Published online Sep 16, 2023. doi: 10.12998/wjcc.v11.i26.6083
Peer-review started: June 20, 2023
First decision: July 7, 2023
Revised: July 12, 2023
Accepted: August 11, 2023
Article in press: August 11, 2023
Published online: September 16, 2023
Processing time: 80 Days and 2 Hours
The incidence and mortality rates of gastric cancer in China are the second-highest in the world, and most patients with gastric cancer lose their chance of surgery by the time of their diagnosis.
To explore the potential of serum basic fibroblast growth factor (bFGF) and interleukin-1β (IL-1β) levels in predicting the effect of first-line chemotherapy in patients with advanced gastric cancer. To evaluate the relationship between the serum levels of bFGF and IL-1β and the therapeutic response to first-line chemotherapy in patients with advanced gastric cancer in order to determine their value as predictive markers.
This prospective study on patients with advanced gastric cancer (as study subjects) was undertaken to provide a reference for the prognosis and anesthesia of clinical-related operations.
Randomized controlled method and double-blinded method. Prior to the initiation of chemotherapy, serum samples are collected from the participants for the determination of the levels of bFGF and IL-1β. Subsequently, the patients underwent first-line chemotherapy, and the treatment response was assessed at the end of the chemotherapy cycle.
Previous reports have suggested that capecitabine + cisplatin has a clear efficacy in advanced gastric cancer, albeit there is a lack of relevant studies on trastuzumab - a drug that targets HER2 tumor cells. The researchers analyzed the association between the serum levels of bFGF and IL-1β and the therapeutic response to first-line chemotherapy. The possible outcomes include poorer treatment response, such as smaller tumor shrinkage or faster disease progression, in patients with higher levels of bFGF and IL-1β after the first-line chemotherapy.
In this study, 86 gastric cancer patients admitted to two hospitals were examined to investigate the efficacy of trastuzumab in combination with cisplatin in the treatment of HER2-positive gastric cancer. Based on the research findings, we suggest that the serum levels of bFGF and IL-1β can serve as predictive markers for the therapeutic response to first-line chemotherapy in patients with advanced gastric cancer. The measurement of these biomarkers can provide additional information to clinicians, thereby assisting in decision-making and the development of personalized treatment plans.
Predictive role of serum bFGF and IL-1β in first-line chemotherapy for advanced gastric cancer.